Baxter International Inc. focuses on a broad array of healthcare products worldwide. The stock is currently rated as "Hold" with moderate potential for growth. Investors should consider both its stable healthcare solutions and presence in over 100 countries.
According to the latest data, Baxter holds a fundamental rating of "C", suggesting average performance. Detailed scores in various financial ratios indicate some challenges in profitability and financial management.
Category | Score | Visual |
---|---|---|
Discounted Cash Flow | 4 | |
Return on Equity | 1 | |
Return on Assets | 1 | |
Debt to Equity | 1 | |
Price to Earnings | 1 | |
Price to Book | 3 |
Comparing recent scores with previous data shows consistency in discount cash flow but stagnation in other areas.
Date | Overall | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-07-03 | 2 | 4 | 1 | 1 | 1 | 1 | 3 |
Previous | 0 | 4 | 1 | 1 | 1 | 1 | 3 |
Analyst estimates show a high target of \$98, with a median at \$44.5, revealing a cautious market approach.
High | Low | Median | Consensus |
---|---|---|---|
$98 | $30 | $44.5 | $59.07 |
Baxter maintains a "Hold" consensus with a balanced distribution of buy and hold recommendations.
Rating | Count | Visual |
---|---|---|
Strong Buy | 0 | |
Buy | 16 | |
Hold | 19 | |
Sell | 1 | |
Strong Sell | 0 |
Baxter International Inc. is a stable entity in the healthcare sector with diverse operations spanning globally. Despite its expansive reach, financial and efficiency metrics suggest room for improvement. The "Hold" recommendation reflects a balanced outlook. Investors should note the company's core strengths in dialysis and critical care products but remain aware of financial constraints impacting potential growth.